Cargando…

Outcomes of allergic-type reactions after messenger RNA coronavirus disease 2019 vaccination at 3 military medical centers

Detalles Bibliográficos
Autores principales:	St. Clair, Benjamin D., Hoffman, Donna L., McClenathan, Bruce, Banks, Taylor, Lee, Rachel U.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. 2022
Materias:	Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9119161/ https://www.ncbi.nlm.nih.gov/pubmed/35598884 http://dx.doi.org/10.1016/j.anai.2022.05.010

Ejemplares similares

Coronavirus disease 2019 messenger RNA vaccine skin tests and serum histamine levels in allergic reactions
por: Kohli-Pamnani, Anita, et al.
Publicado: (2022)

Antibody response to graded dosing of coronavirus disease 2019 messenger RNA vaccines after allergic reaction to first dose
por: Van Meerbeke, Sara W., et al.
Publicado: (2022)

Differential Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Profiles After Allergic Reactions to Messenger RNA Coronavirus Disease 2019 Vaccine( )
por: Maron, Jenny S, et al.
Publicado: (2022)

Disproportionality analysis of anaphylactic reactions after vaccination with messenger RNA coronavirus disease 2019 vaccines in the United States
por: Rodriguez-Nava, Guillermo, et al.
Publicado: (2021)

Utility and futility of skin testing to address concerns surrounding messenger RNA coronavirus disease 2019 vaccine reactions
por: Pitlick, Mitchell M., et al.
Publicado: (2022)

Coronavirus Disease 2019 Messenger RNA Vaccine Immunogenicity in Immunosuppressed Individuals
por: Collier, Ai-ris Y, et al.
Publicado: (2021)

Outcomes of Coronavirus Disease 2019 Drive-Through Screening at an Academic Military Medical Center
por: Lindholm, David A, et al.
Publicado: (2020)

Isoniazid-Induced Severe Hepatotoxicity: An Infrequent but Preventable Cause of Liver Failure in Children Treated for Latent Tuberculosis Infection
por: Desrochers, Dan, et al.
Publicado: (2011)

Risk of allergic reaction in patients with atopic disease and recent coronavirus disease 2019 vaccination
por: Dages, Kelley N., et al.
Publicado: (2021)

Allergic reactions to coronavirus disease 2019 vaccines and addressing vaccine hesitancy: Northwell Health experience
por: Kaplan, Blanka, et al.
Publicado: (2022)

Antibody response to coronavirus disease 2019 vaccines after allergic reaction to first dose: Correspondence
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

2200. Impact of COVID-19 Pandemic on Influenza-like Illness (ILI) Experience among Healthcare Workers in Military Treatment Facilities
por: Liberg, Ryan, et al.
Publicado: (2022)

Skin Adverse Reactions to Novel Messenger RNA Coronavirus Vaccination: A Case Series
por: Peigottu, Maria Francesca, et al.
Publicado: (2021)

Adverse Reactions after BNT162b2 Messenger RNA Vaccination for Coronavirus Disease 2019 in Healthcare Workers Compared with Influenza Vaccination
por: Kim, A-Sol, et al.
Publicado: (2023)

Immune parameters during anaphylaxis to messenger RNA coronavirus disease 2019 vaccines: Not the usual suspects?
por: de Chaisemartin, Luc, et al.
Publicado: (2022)

Effectiveness of Messenger RNA-1273 Vaccine Booster Against Coronavirus Disease 2019 in Immunocompetent Adults
por: Florea, Ana, et al.
Publicado: (2022)

Evaluation of anaphylaxis risk by skin testing with coronavirus disease 2019 messenger RNA vaccines on patients with anaphylaxis
por: Pienkowski, Marek M., et al.
Publicado: (2022)

Myopericarditis after messenger RNA Coronavirus Disease 2019 Vaccination in Adolescents 12 to 18 Years of Age
por: Das, Bibhuti B., et al.
Publicado: (2021)

Long-term evaluation of sperm parameters after coronavirus disease 2019 messenger ribonucleic acid vaccination
por: Diaz, Parris, et al.
Publicado: (2022)

Risk of myocarditis and pericarditis following coronavirus disease 2019 messenger RNA Vaccination—A nationwide study
por: Su, Wei-Ju, et al.
Publicado: (2023)

Allergic reactions to the coronavirus disease 2019 vaccine (ARCOV) study: The McGill University Health Centre experience
por: ALMuhizi, Faisal, et al.
Publicado: (2022)

1715. Influenza-like Illness (ILI) Experience Among Healthcare Workers in Military Treatment Facilities: An Offshoot of the Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD (PAIVED) Study
por: Colombo, Rhonda, et al.
Publicado: (2020)

Acute pulmonary thromboembolism after messenger RNA vaccination against coronavirus disease 2019: A case report
por: Ishibashi, Yohei, et al.
Publicado: (2023)

Call to Duty: US Military Plastic Surgery Response to the Coronavirus Disease 2019 Pandemic
por: Farber, Scott, et al.
Publicado: (2020)

Myocarditis and pericarditis recovery following smallpox vaccine 2002–2016: A comparative observational cohort study in the military health system
por: Engler, Renata J. M., et al.
Publicado: (2023)

Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies
por: Wong, Serre-Yu, et al.
Publicado: (2021)

Multisystem Inflammation and Organ Dysfunction After BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccination
por: Kahn, Benjamin, et al.
Publicado: (2021)

Multidisciplinary diagnostic approach for fulminant myocarditis related to coronavirus disease 2019 messenger RNA vaccines: a case report
por: Fujii, Masayoshi, et al.
Publicado: (2023)

The Cell Collective: Toward an open and collaborative approach to systems biology
por: Helikar, Tomáš, et al.
Publicado: (2012)

Longitudinal Neutralizing and Functional Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Variants Following Messenger RNA Coronavirus Disease 2019 Vaccination
por: Chen, Xuemin, et al.
Publicado: (2023)

Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Medical Use of Military Hospitals in Korea
por: Yoon, Doran, et al.
Publicado: (2021)

Messengers of light : the angels' guide to spiritual growth /
por: Taylor, Terry Lynn, 1955-
Publicado: (1989)

Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era
por: Agha, Mounzer E, et al.
Publicado: (2021)

Immunogenicity and Reactogenicity of Messenger RNA Coronavirus Disease 2019 Vaccine Booster Administered by Intradermal or Intramuscular Route in Thai Older Adults
por: Assantachai, Prasert, et al.
Publicado: (2023)

Risk of Coronavirus Disease 2019 Messenger RNA Vaccination-Associated Myocarditis and Pericarditis – A Systematic Review of Population-Based Data
por: Lin, Yen-Ching, et al.
Publicado: (2023)

Asthma and allergic diseases are not risk factors for hospitalization in children with coronavirus disease 2019
por: Beken, Burcin, et al.
Publicado: (2021)

Hypersensitivity reactions following the Moderna messenger RNA-1273 vaccine
por: Drohan, Alex, et al.
Publicado: (2021)

Treatment of allergic reactions to peanut in recent versus initial reaction
por: Ben-Shoshan, Moshe, et al.
Publicado: (2010)

Side effects and antibody titer transition of the BNT162b2 messenger ribonucleic acid coronavirus disease 2019 vaccine in Japan
por: Izumo, Takehiro, et al.
Publicado: (2021)

Biphasic anaphylaxis after first dose of messenger RNA coronavirus disease 2019 vaccine with positive polysorbate 80 skin testing result
por: Pitlick, Mitchell M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ut39pu6hrb6ld10r44qdu34q1s